Add Yahoo as a preferred source to see more of our stories on Google. In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, ...

Young men who have sex with men (YMSM) said the treatment’s efficacy was the most important feature injectable HIV pre-exposure prophylaxis (PrEP), over side effects, cost, protection duration, and ...

The burden of taking a daily dose of PrEP might soon be lifted. According to updated CDC guidelines, bi-monthly injectable PrEP is expected to receive FDA approval by February. The injectable ...

Michael Montess receives funding from the Canadian Institutes of Health Research, Mitacs, the Social Sciences and Humanities Research Council, and the Michael Smith Foundation for Health Research. He ...

ViiV expects injectables to steal significant market share from oral treatments, such as Gilead’s Biktarvy, which currently dominate the HIV field. In the prevention arena, the company is awaiting an ...

The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention. The shots, which are administered by a ...

Add Yahoo as a preferred source to see more of our stories on Google. Ian L. Haddock founder of the normal anomaly I was born in Galveston County, Texas, the very place where, on June 19, 1865, ...

Men who have sex with men (MSM) who are HIV-negative reported interest in an injectable pre-exposure prophylaxis (PrEP) that lasted longer than the daily pill, regardless of cost or coverage. This ...

The US Food and Drug Administration has approved a form of PrEP that requires injections every two months, rather than a daily pill. PrEP, or pre-exposure prophylaxis, uses antiretroviral medications ...

Please provide your email address to receive an email when new articles are posted on . Among nearly 2,500 women, almost 80% chose long-acting, injectable cabotegravir for HIV PrEP. Reasons included ...

A recent study of injectable pre-exposure prophylaxis found that twice-yearly injections of lenacapavir — marketed as Yeztugo by Gilead Sciences — do not have clinically significant interactions with ...

Patients are already receiving the new PrEP injectable option lenacapavir in the Bay Area, though issues with insurance are complicating the process of getting shots. The new injectable was approved ...